Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G versus GRIFULVIN V.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G versus GRIFULVIN V.
FULVICIN P/G vs GRIFULVIN V
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
Binds to microtubule-associated proteins and disrupts fungal mitotic spindle formation, thereby inhibiting fungal cell division. It also interferes with fungal nucleic acid synthesis.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
500 mg orally once daily (non-microsize formulation) or 250 mg twice daily; typical duration is 4-8 weeks for tinea capitis, 2-6 weeks for tinea corporis, 4-6 weeks for tinea pedis.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
Terminal half-life: 9–24 hours. Clinical context: Steady-state achieved in 2–5 days; prolonged in hepatic impairment.
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
Renal (1% unchanged), fecal (33% as metabolites), biliary (minor). Extensive hepatic metabolism; <1% excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal